All Baxalta articles
-
BusinessShire bets big on rare diseases
$32bn Baxalta buyout will deepen Shire’s commitment to developing specialist drugs for small patient populations
-
BusinessMerger fever sweeps pharma
The life sciences sector has been gripped by a mergers and acquisition frenzy, and it looks set to continue. But what does it mean for the industry?
-
Business
Shire makes hostile bid for Baxalta
Recently spun-out from Baxter, Baxalta is resisting the deal, saying it wants time to prove its true value
-
-
Business
Baxter aims to divide and conquer
Firm will split off its biopharmaceuticals business from medical products